An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma-Reference-Cited by-同舟云学术

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Published:2021-04-06 Issue:1 Volume:20 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Reggiani Francesca,Sauta Elisabetta,Torricelli Federica,Zanetti Eleonora,Tagliavini Elena,Santandrea Giacomo,Gobbi Giulia,Damia Giovanna,Bellazzi Riccardo,Ambrosetti Davide,Ciarrocchi Alessia,Sancisi Valentina^ORCID

Funder

Ministero della Salute

Fondazione Umberto Veronesi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12943-021-01357-z.pdf

Reference17 articles.

1. Uprety D, Parikh K, Sawkar A, Dimou A, Leventakos K. Changing paradigm in advanced and metastatic non-small cell lung cancer. J Thorac Dis. 2020;12(11):6992–7001. https://doi.org/10.21037/jtd-20-1472.

2. Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Mechanisms of Resistance to KRAS(G12C) Inhibitors. Cancers (Basel). 2021;13(1):151.

3. Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6(3):316–29. https://doi.org/10.1158/2159-8290.CD-15-1105.

4. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–17. https://doi.org/10.1056/NEJMoa1917239.

5. Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, et al. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019;38(42):6801–17.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A deep learning and docking simulation-based virtual screening strategy enables the rapid identification of HIF-1α pathway activators from a marine natural product database;Journal of Biomolecular Structure and Dynamics;2023-04-10

2. KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM);NAR Cancer;2022-06-29

3. The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation;Oncogene;2022-06-15

4. Construction of a hypoxia-immune-related prognostic model and targeted therapeutic strategies for cervical cancer;International Immunology;2022-05-13

5. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner;Cancers;2022-03-23